Overview

Study to Evaluate CCS1477 in Haematological Malignancies

Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
CellCentric Ltd.